MAO/F CLONING AND PRODUCTION OF HIV-1 ENVELOPE PROTEINS

HIV-1 包膜蛋白的 MAO/F 克隆和生产

• 批准号: 2662808
• 负责人: WILLIAM C OLSON
• 金额: $ 73.86万
• 依托单位: PROGENICS PHARMACEUTICALS, INC.
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-30 至 1999-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2662808
• 关键词: AIDS vaccines; HIV envelope protein; guinea pigs; human immunodeficiency virus 1; laboratory mouse; laboratory rabbit; molecular cloning; protein engineering; protein purification; simian immunodeficiency virus; transfection /expression vector; vaccine development

The envelope protein of HIV is considered an integral target of AIDS vaccine design. Since this proteins is present on virus particles and infected cells, it is reasonable to predict that immunity raised to env will be a quintessential part of any vaccine, if not essential. A problem with this however, is that different HIV clades have different envelope proteins that can be recognized as different to the immune system. Also, the envelops can exist in different structural forms. The objectives of this contract will be to clone various specific envelope genes of HIV and engineer expression vectors capable of expressing the given envelope proteins in vitro. Next, these envelope proteins will be purified so as to permit their administration to experimental animals to test their immunogenicity. Different forms, monomeric and oligomeric, will be generated and purified. The particular env genes will be identified by the Project Officer.

HIV的包膜蛋白被认为是艾滋病的一个重要靶点 疫苗设计。由于这种蛋白质存在于病毒颗粒上， 被感染的细胞，可以合理地预测免疫力提高到环境 将是任何疫苗的典型组成部分，如果不是必不可少的话。一个问题 然而，不同的艾滋病毒分支有不同的包膜 可以被识别为与免疫系统不同的蛋白质。 此外，包络可以以不同的结构形式存在。这个 本合同的目标是复制各种特定的信封 HIV基因及可表达的工程表达载体 给出的包膜蛋白在体外。接下来，这些包膜蛋白将 对其进行提纯，以便将其用于实验性给药 动物来测试它们的免疫原性。不同的形式，单体和 低聚物，将被产生和提纯。特定的env基因 将由项目官员确定。